Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Single-center, Randomized, Double-masked, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of G01 Eye Drops Following Single and Multiple Administrations in Healthy Subjects.

NCT07779902 is registered in ClinicalTrials.gov with Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. as lead sponsor.

NCT NCT07779902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07779902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Single-center, Randomized, Double-masked, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of G01 Eye Drops Following Single and Multiple Administrations in Healthy Subjects.
Lead sponsor
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 12, 2024
Completion date
June 28, 2025
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healhty